Fig. 6
From: An mRNA-based rabies vaccine induces strong protective immune responses in mice and dogs
Pre-exposure immunization of LVRNA001 efficiently protected dogs from live virus infection. Dogs were intramuscularly immunized twice (0d/7d) or three times (0d/7d/21d) with LVRNA001 (5 μg or 25 μg dosages), five times (0d/3d/7d/14d/28d) with inactivated vaccine, or PBS. A Serum samples from dogs were collected at 7, 9, 11, 13, and 35 dpi, FAVN tests were conducted to detect neutralizing antibody levels. B Dogs were challenged with 50-fold LD50 of the virulent RABV-BD06 strain by i.m. injection at 35 dpi. The survival rates were calculated at 3 months post-challenge. C Neutralizing antibody levels in the surviving dogs at 3 months post-challenge were measured using FAVN test. n = 6/group